ARS Pharmaceuticals Submits Response For neffy Marketing Authorization Application To EMA's CHMP And Enters License Agreement With CSL Seqirus For Commercialization Of neffy In Australia And New Zealand
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has submitted a response for the Marketing Authorization Application (MAA) of neffy to the EMA's CHMP, addressing all previously identified issues. The company anticipates a CHMP opinion in Q2 2024. Additionally, ARS Pharmaceuticals entered into an exclusive licensing agreement with CSL Seqirus, a subsidiary of CSL Limited (ASX:CSL), for the commercialization of neffy in Australia and New Zealand. CSL Seqirus will handle regulatory approval, reimbursement, and commercialization, while ARS Pharmaceuticals will manage manufacturing and supply. The agreement includes an upfront payment to ARS Pharmaceuticals and event-driven milestone payments.
April 30, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CSL Limited, through its subsidiary CSL Seqirus, has entered into an exclusive licensing agreement with ARS Pharmaceuticals for the commercialization of neffy in Australia and New Zealand.
The partnership with ARS Pharmaceuticals to commercialize neffy in Australia and New Zealand could enhance CSL Limited's product portfolio and market presence in the allergy treatment sector, likely having a positive impact on its stock value.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
ARS Pharmaceuticals has submitted a crucial response for neffy's MAA to the EMA and entered a significant licensing agreement with CSL Seqirus for commercialization in Australia and New Zealand.
The submission to the EMA's CHMP and the licensing agreement with CSL Seqirus are significant steps towards global commercialization of neffy, potentially boosting investor confidence and stock value in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100